Abstract
In deceased donors, Ischemia/Reperfusion Injury (IRI) is an important cause of allograft dysfunction. Prolonged cold and warm ischemia time leads to a high risk of early post-transplant complications, including acute and chronic rejection. Ischemia not only up-regulates inflammatory cytokines and chemokines, but also enhances the expression of MHC-class II and adhesion molecules on epithelial and dendritic cells. Moreover, the Danger Associated Molecular Patterns (DAMPs) released from stressed or dying cells, not only cause or amplify tissue inflammation and trigger tissue repair in response to IRI, but also act as adjuvants that enhance DC maturation and potentiate the adaptive immune response. In this review, we will also discuss about whether donor or recipient DCs are more important in the process of ischemia enhanced acute rejection.
Keywords: Dendritic cells, Kidney transplantation, Allograft rejection, Ischemia/reperfusion injury, APC, CTLs.
Current Gene Therapy
Title:How Do Dendritic Cells Play the Role in Ischemia/Reperfusion Triggered Kidney Allograft Rejection
Volume: 17 Issue: 6
Author(s): Songjie Cai*, Naotsugu Ichimaru and Shiro Takahara*
Affiliation:
- Department of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Osaka,Japan
- Department of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Osaka,Japan
Keywords: Dendritic cells, Kidney transplantation, Allograft rejection, Ischemia/reperfusion injury, APC, CTLs.
Abstract: In deceased donors, Ischemia/Reperfusion Injury (IRI) is an important cause of allograft dysfunction. Prolonged cold and warm ischemia time leads to a high risk of early post-transplant complications, including acute and chronic rejection. Ischemia not only up-regulates inflammatory cytokines and chemokines, but also enhances the expression of MHC-class II and adhesion molecules on epithelial and dendritic cells. Moreover, the Danger Associated Molecular Patterns (DAMPs) released from stressed or dying cells, not only cause or amplify tissue inflammation and trigger tissue repair in response to IRI, but also act as adjuvants that enhance DC maturation and potentiate the adaptive immune response. In this review, we will also discuss about whether donor or recipient DCs are more important in the process of ischemia enhanced acute rejection.
Export Options
About this article
Cite this article as:
Cai Songjie *, Ichimaru Naotsugu and Takahara Shiro *, How Do Dendritic Cells Play the Role in Ischemia/Reperfusion Triggered Kidney Allograft Rejection, Current Gene Therapy 2017; 17 (6) . https://dx.doi.org/10.2174/1566523218666180214095956
DOI https://dx.doi.org/10.2174/1566523218666180214095956 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coronary Microcirculation in Ischemic Heart Disease
Current Pharmaceutical Design Exercise as a platform for pharmacotherapy development in cardiac diseases
Current Pharmaceutical Design Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology Cysteinyl Leukotrienes (CysLTs): Role in Obesity-Induced Asthma
Current Molecular Medicine Synthesis and Biological Activity of Prostaglandin Analogs Containing Heteroatoms in the Cyclopentane Ring
Current Organic Chemistry An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy
Medicinal Chemistry Radial Approach for Percutaneous Coronary Intervention
Reviews on Recent Clinical Trials Metabolic Control of Type 2 Diabetes by Targeting the GLUT4 Glucose Transporter: Intervention Approaches
Current Pharmaceutical Design Extra-Hematopoietic Effects of Erythropoietin
Cardiovascular & Hematological Disorders-Drug Targets Protective Effects of Corticosteroids and Neurosteroids on Cochlear injury
Medicinal Chemistry Facing Up the ROS Labyrinth - Where To Go?
Current Vascular Pharmacology Off-Pump Coronary Artery Bypass Grafting; is it Still Relevant?
Current Cardiology Reviews Myogenic Tone as a Therapeutic Target for Ischemic Stroke
Current Vascular Pharmacology Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Artificial Hibernation by Phenothiazines: A Potential Neuroprotective Therapy Against Cerebral Inflammation in Stroke
Current Neurovascular Research Neuroprotection for Ischemic Injury in the Immature Brain
Current Pediatric Reviews Pulmonary Hypertension in the Critically Ill
Current Hypertension Reviews KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
Current Neuropharmacology Metabolic Therapy of Heart Failure
Current Pharmaceutical Design